XML 27 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 01, 2021
Jan. 03, 2020
Current assets:    
Cash and cash equivalents $ 319,217 $ 266,501
Short-term investments 887,319 585,742
Trade receivables, net 160,875 119,073
Inventory 20,973 12,886
Prepaid expenses and other current assets 57,011 26,988
Total current assets 1,445,395 1,011,190
Long-term investments 332,306 536,385
Property and equipment, net 67,384 48,892
Deferred tax assets, net 156,711 172,374
Goodwill 63,684 63,684
Other long-term assets 71,853 53,145
Total assets 2,137,333 1,885,670
Current liabilities:    
Accounts payable 23,632 11,581
Accrued compensation and benefits 51,189 37,364
Accrued clinical trial liabilities 52,251 38,777
Rebates and fees due to customers 20,683 18,719
Accrued collaboration liabilities 12,456 11,856
Other current liabilities 44,447 24,449
Total current liabilities 204,658 142,746
Long-term portion of deferred revenue 3,755 6,596
Long-term portion of operating lease liabilities 49,086 48,011
Other long-term liabilities 721 2,347
Total liabilities 258,220 199,700
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 311,627 and 304,831 at December 31, 2020 and 2019, respectively 312 305
Additional paid-in capital 2,321,895 2,241,947
Accumulated other comprehensive income 4,476 3,069
Accumulated deficit (447,570) (559,351)
Total stockholders’ equity 1,879,113 1,685,970
Total liabilities and stockholders’ equity $ 2,137,333 $ 1,885,670